Tetra Bio-Pharma’s PPP004 receives orphan drug status

Tetra Bio-Pharma’s PPP004, a cannabinoid-derived cream, has been granted Orphan Drug Designation by the European Medicines Agency (EMA).

EMA Orphan Drug Designation supports the development of investigational products that are intended to treat rare diseases affecting fewer than 5 in 10,000 people.

Read the press release from Tetra Bio-Pharma.